NCT06858839 (MARITIME-1) is a Phase 3 clinical trial of Maridebart Cafraglutide in Obesity, sponsored by Amgen.

Who is sponsoring NCT06858839?

NCT06858839 is sponsored by Amgen.

What drugs are being tested in NCT06858839?

Interventions in NCT06858839: Maridebart Cafraglutide, Placebo.

Is NCT06858839 still recruiting?

NCT06858839 is currently active, enrolled. Last updated 20 October 2025.

Last reviewed 2025-10-20 · How we verify

NCT06858839: MARITIME-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Active, enrolled Phase 3 Last updated 20 October 2025

What this trial tests

Phase 3 trial testing Maridebart Cafraglutide in Obesity in 3,853 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

12 March 2025

Primary endpoint
21 January 2027

16 April 2027

Quick facts

Lead sponsor	Amgen
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	3,853
Start date	12 March 2025
Primary completion	21 January 2027
Estimated completion	16 April 2027
Sites	243 locations across Denmark, Italy, Finland, Japan, Belgium, United Kingdom, Germany, Poland

Drugs / interventions tested

Maridebart Cafraglutide — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 99, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Maridebart Cafraglutide

Trials testing the same drug.

NCT07523711 — Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Fe · Phase 1 · not yet recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07229157 — Effect of Maridebart Cafraglutide on the Heart's Electrical Activity · Phase 1 · active not recruiting
NCT07226778 — Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Tw · Phase 1 · active not recruiting
NCT07037433 — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov · Phase 3 · recruiting

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06858839 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 20 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06858839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing